All AbMole products are for research use only, cannot be used for human consumption.
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
Human ROR1 HEK293T cells were stained with Zilovertamab vedotin and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.05656 ug/ml.
Human ROR1 CHO-K Cell Line were stained with zilovertamab vedotin and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.03245 ug/mL.
Zilovertamab vedotin inhibited the tumor growth of MDA-MB-231on NSG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 96.6% at 10 mpk.
| CAS Number | 2376463-48-6 |
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
[1] Anita Kumar, et al. Am Soc Clin Oncol Educ Book. New Directions for Mantle Cell Lymphoma in 2022
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Oregovomab-MMAE
Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
| Patritumab-MMAE
Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE. |
| Depatuxizumab mafodotin
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII. |
| Ozuriftamab vedotin
Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE. |
| Glembatumumab vedotin
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
